Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.


Stanford L Peng, MD, PhD
Section Editor
Mark H Wener, MD
Deputy Editor
Monica Ramirez Curtis, MD, MPH


When plasma is refrigerated at 4ºC for up to 72 hours, proteins may precipitate (cryoprecipitate). If refrigerated serum and plasma both form a precipitate, then the precipitated proteins are referred to as cryoglobulins (CGs). If, however, precipitation develops after refrigeration of plasma but does not occur in cold serum, the plasma precipitate is referred to as cryofibrinogen (CF).

Cryoprecipitates — Both CGs and CF typically redissolve with warming to 37ºC, but the components of CF and CG differ. CGs typically contain immunoglobulins and complement components. Although CF may also contain immunoglobulins, CF is characteristically composed of fibrinogen, fibrin, fibronectin and/or fibrin degradation products [1-3]. By definition, CF is undetectable in serum.

Some cryoprecipitates, particularly CGs, may not completely redissolve when warmed. The residual material may be composed of fibrin.

Cryoglobulinemia — As defined above, a person whose serum and plasma form cryoprecipitates is referred to as having cryoglobulinemia. Three different types of CGs are recognized and the pathogenesis, clinical manifestations, and treatment associated with each type are discussed elsewhere. The following is a brief summary of the types of cryoglobulinemia (see "Overview of cryoglobulins and cryoglobulinemia", section on 'Classification'):

Type I cryoglobulinemia, in which there is a monoclonal immunoglobulin that is most often due to an underlying B cell proliferative disorder such as multiple myeloma or Waldenström’s macroglobulinemia. (See "Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia" and "Clinical features, laboratory manifestations, and diagnosis of multiple myeloma".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Jun 02, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. KORST DR, KRATOCHVIL CH. Cryofibrinogen in a case of lung neoplasm associated with thrombophlebitis migrans. Blood 1955; 10:945.
  2. Komp DM, Donaldson MH. The relationship between fibrinogen degradation products and cryofibrinogen. Am J Pediatr Hematol Oncol 1979; 1:99.
  3. Stathakis NE, Karamanolis D, Koukoulis G, Tsianos E. Characterization of cryofibrinogen isolated from patients plasma. Haemostasis 1981; 10:195.
  4. Tissot JD, Invernizzi F, Schifferli JA, et al. Two-dimensional electrophoretic analysis of cryoproteins: a report of 335 samples. Electrophoresis 1999; 20:606.
  5. Blain H, Cacoub P, Musset L, et al. Cryofibrinogenaemia: a study of 49 patients. Clin Exp Immunol 2000; 120:253.
  6. Martin S. Cryofibrinogenemia, monoclonal gammopathy, and purpura. Report of a case and review of the literature. Arch Dermatol 1979; 115:208.
  7. Komp DM, Donaldson MH. In vitro and in vivo effects of heparin on cryofibrinogen. N Engl J Med 1968; 279:1439.
  8. Stathakis NE, Mosesson MW. Interactions among heparin, cold-insoluble globulin, and fibrinogen in formation of the heparin-precipitable fraction of plasma. J Clin Invest 1977; 60:855.
  9. Hobbs JR. Cryoproteins. Ann Med Interne (Paris) 1986; 137:254.
  10. Kalivas J. Testing for cryofibrinogenemia. J Dermatol Surg Oncol 1979; 5:361.
  11. Michaud M, Pourrat J. Cryofibrinogenemia. J Clin Rheumatol 2013; 19:142.
  12. Belizna C, Loufrani L, Subra JF, et al. A 5-year prospective follow-up study in essential cryofibrinogenemia patients. Autoimmun Rev 2011; 10:559.
  13. Lolin Y, Razis PA, O'Gorman P, et al. Transient nephrotic syndrome after anaesthesia resulting from a familial cryofibrinogen precipitating at 35 degrees C. J Med Genet 1989; 26:631.
  14. Wulffraat N, Meyer KJ, Zegers BJ, Kuis W. Familial presence of primary cryofibrinogenaemia, a report of three cases. Br J Rheumatol 1996; 35:102.
  15. van Geest AJ, van Dooren-Greebe RJ, Andriessen MP, et al. Familial primary cryofibrinogenemia. J Eur Acad Dermatol Venereol 1999; 12:47.
  16. Matsuda M, Saida T, Hasegawa R. Cryofibrinogen in the plasma of patients with skin ulcerative lesions on the legs: a complex of fibrinogen and cold insoluble globulin. Thromb Res 1976; 9:541.
  17. McKee PK, Kalbfleisch JM, Bird RM. Incidence and significance of cryofibrinogenemia. J Lab Clin Med 1963; 61:203.
  18. Zlotnick A, Shahin W, Rachmilewitz EA. Studies in cryofibrinogenemia. Acta Haematol 1969; 42:8.
  19. Smith SB, Arkin C. Cryofibrinogenemia: incidence, clinical correlations, and a review of the literature. Am J Clin Pathol 1972; 58:524.
  21. Rachmilewitz EA, Sacks MI, Zlotnick A. Essential cryofibrinogenemia. Clinical, pathological and immunological studies. Isr J Med Sci 1970; 6:32.
  22. Ireland TA, Werner DA, Rietschel RL, et al. Cutaneous lesions in cryofibrinogenemia. J Pediatr 1984; 105:67.
  23. Crowson AN, Magro CM. Idiopathic perniosis and its mimics: a clinical and histological study of 38 cases. Hum Pathol 1997; 28:478.
  24. Saadoun D, Elalamy I, Ghillani-Dalbin P, et al. Cryofibrinogenemia: new insights into clinical and pathogenic features. Am J Med 2009; 122:1128.
  25. McGrath MA, Wechsler F, Hunyor AB, Penny R. Systemic factors contributory to retinal vein occlusion. Arch Intern Med 1978; 138:216.
  26. Tsai RK, Chang CH. Central retinal vein occlusion associated with cryofibrinogenemia in a young adult--study of skin dynamic capillaroscopy. J Formos Med Assoc 1998; 97:777.
  27. Delluc A, Saadoun D, Ghillani-Dalbin P, et al. Cryofibrinogen in patients with hepatitis C virus infection. Am J Med 2008; 121:624.
  28. Michaud M, Moulis G, Puissant B, et al. Cryofibrinogenemia: a marker of severity of cryoglobulinemic vasculitis. Am J Med 2015; 128:916.
  29. Jantunen E, Soppi E, Neittaanmäki H, Lahtinen R. Essential cryofibrinogenaemia, leukocytoclastic vasculitis and chronic purpura. J Intern Med 1993; 234:331.
  30. Nash JW, Ross P Jr, Neil Crowson A, et al. The histopathologic spectrum of cryofibrinogenemia in four anatomic sites. Skin, lung, muscle, and kidney. Am J Clin Pathol 2003; 119:114.
  31. Euler HH, Zeuner RA, Béress R, et al. Monoclonal cryo-antifibrinogenemia. Arthritis Rheum 1996; 39:1066.
  32. Amdo TD, Welker JA. An approach to the diagnosis and treatment of cryofibrinogenemia. Am J Med 2004; 116:332.
  33. Falanga V, Kirsner RS, Eaglstein WH, et al. Stanozolol in treatment of leg ulcers due to cryofibrinogenaemia. Lancet 1991; 338:347.
  34. Klein AD, Kerdel FA. Purpura and recurrent ulcers on the lower extremities. Essential cryofibrinogenemia. Arch Dermatol 1991; 127:115, 118.
  35. Kirsner RS, Eaglstein WH, Katz MH, et al. Stanozolol causes rapid pain relief and healing of cutaneous ulcers caused by cryofibrinogenemia. J Am Acad Dermatol 1993; 28:71.
  36. Helfman T, Falanga V. Stanozolol as a novel therapeutic agent in dermatology. J Am Acad Dermatol 1995; 33:254.
  37. Rubegni P, Flori ML, Fimiani M, Andreassi L. A case of cryofibrinogenaemia responsive to stanozolol. Br J Haematol 1996; 93:217.
  38. Sankarasubbaiyan S, Scott G, Holley JL. Cryofibrinogenemia: an addition to the differential diagnosis of calciphylaxis in end-stage renal disease. Am J Kidney Dis 1998; 32:494.
  39. Siami GA, Siami FS. Plasmapheresis and paraproteinemia: cryoprotein-induced diseases, monoclonal gammopathy, Waldenström's macroglobulinemia, hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis. Ther Apher 1999; 3:8.
  40. Moraru M, Yebra-Bango M, Cisneros E, et al. Cryofibrinogenemia triggered by a monoclonal paraprotein successfully treated with cyclophosphamide. J Clin Rheumatol 2014; 20:34.
  41. Browning CE, Callen JP. Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia. Arch Dermatol 2006; 142:75.
  42. Copeman PW. Cryofibrinogenaemia and skin ulcers: treatment with plasmapheresis. Br J Dermatol 1979; 101 Suppl 17:57.
  43. Siami FS, Siami GA. Cryofiltration apheresis in the treatment of cryoprecipitate induced diseases. Ther Apher 1997; 1:58.
  44. Bair JS, Wu YC, Lü YC. Cryofibrinogenemia: report of a case. J Formos Med Assoc 1991; 90:99.
  45. Young GD, Cleland LG, McNeil JD. Cryofibrinogenaemia: a case report. Aust N Z J Med 1991; 21:444.
  46. Lazar AP, Lazar P. Giardiasis, cryofibrinogenemia, and cold sensitivity: a response to metronidazole. Int J Dermatol 1991; 30:598.
  47. Stavem P, Rørvik T, Brandtzaeg P, et al. Gastric lymphoma causing granulocytopenia and cold intolerance, with recovery after treatment. J Intern Med 1991; 229:193.